DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,999 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $8,901,641 | +16.5% | 35,628 | +16.5% | 0.12% | +9.1% |
Q1 2024 | $7,640,023 | +17.4% | 30,594 | +8.8% | 0.11% | +1.9% |
Q4 2023 | $6,507,950 | -3.6% | 28,132 | +3.4% | 0.11% | -21.2% |
Q3 2023 | $6,748,017 | +9.8% | 27,198 | +6.2% | 0.14% | +10.5% |
Q2 2023 | $6,146,527 | -14.8% | 25,610 | -10.5% | 0.12% | -25.7% |
Q1 2023 | $7,210,751 | -5.1% | 28,610 | -0.0% | 0.17% | -21.6% |
Q4 2022 | $7,596,526 | +1.5% | 28,622 | -1.2% | 0.21% | +3.9% |
Q3 2022 | $7,483,000 | +99.1% | 28,970 | +95.4% | 0.20% | +79.8% |
Q2 2022 | $3,759,000 | -33.4% | 14,827 | -23.0% | 0.11% | -15.6% |
Q1 2022 | $5,647,000 | -6.5% | 19,251 | +4.9% | 0.14% | -3.6% |
Q4 2021 | $6,039,000 | +14.7% | 18,355 | +6.2% | 0.14% | 0.0% |
Q3 2021 | $5,263,000 | +24.4% | 17,289 | +9.7% | 0.14% | +12.9% |
Q2 2021 | $4,230,000 | +39.6% | 15,762 | +17.0% | 0.12% | -0.8% |
Q1 2021 | $3,031,000 | +12.0% | 13,468 | +7.1% | 0.12% | -14.4% |
Q3 2020 | $2,707,000 | +19.5% | 12,573 | -1.8% | 0.15% | -0.7% |
Q2 2020 | $2,265,000 | +20.7% | 12,807 | -5.6% | 0.15% | -2.6% |
Q1 2020 | $1,877,000 | -2.7% | 13,566 | +7.9% | 0.15% | -10.7% |
Q4 2019 | $1,929,000 | – | 12,571 | – | 0.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ace Management Global Ltd. | 168,488 | $42,096,727 | 12.36% |
Zeno Equity Partners LLP | 182,612 | $45,660,122 | 12.15% |
Defender Capital, LLC. | 135,187 | $33,776,567 | 11.54% |
Bancreek Capital Management, LP | 56,267 | $14,058,310 | 10.98% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 214,830 | $53,664,407 | 9.84% |
CADEN CAPITAL PARTNERS, LP | 104,501 | $26,109,575 | 9.44% |
Dorsey Asset Management | 306,420 | $76,559,037 | 9.12% |
Consulta Ltd | 500,000 | $124,925,000 | 8.51% |
BOONE CAPITAL MANAGEMENT LLC | 106,360 | $26,574,046 | 6.93% |
Manchester Global Management (UK) Ltd | 150,688 | $37,649,397 | 6.62% |